1. Home
  2. CTNM vs LFCR Comparison

CTNM vs LFCR Comparison

Compare CTNM & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • LFCR
  • Stock Information
  • Founded
  • CTNM 2009
  • LFCR 1986
  • Country
  • CTNM United States
  • LFCR United States
  • Employees
  • CTNM N/A
  • LFCR N/A
  • Industry
  • CTNM
  • LFCR Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTNM
  • LFCR Health Care
  • Exchange
  • CTNM Nasdaq
  • LFCR Nasdaq
  • Market Cap
  • CTNM 114.1M
  • LFCR N/A
  • IPO Year
  • CTNM 2024
  • LFCR N/A
  • Fundamental
  • Price
  • CTNM $3.87
  • LFCR $6.97
  • Analyst Decision
  • CTNM Strong Buy
  • LFCR Buy
  • Analyst Count
  • CTNM 4
  • LFCR 3
  • Target Price
  • CTNM $23.75
  • LFCR $8.00
  • AVG Volume (30 Days)
  • CTNM 86.8K
  • LFCR 208.5K
  • Earning Date
  • CTNM 05-16-2025
  • LFCR 04-03-2025
  • Dividend Yield
  • CTNM N/A
  • LFCR N/A
  • EPS Growth
  • CTNM N/A
  • LFCR N/A
  • EPS
  • CTNM N/A
  • LFCR N/A
  • Revenue
  • CTNM N/A
  • LFCR $130,309,000.00
  • Revenue This Year
  • CTNM N/A
  • LFCR $1.57
  • Revenue Next Year
  • CTNM N/A
  • LFCR $3.98
  • P/E Ratio
  • CTNM N/A
  • LFCR N/A
  • Revenue Growth
  • CTNM N/A
  • LFCR 7.23
  • 52 Week Low
  • CTNM $3.69
  • LFCR $3.68
  • 52 Week High
  • CTNM $22.00
  • LFCR $7.99
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • LFCR 57.87
  • Support Level
  • CTNM N/A
  • LFCR $6.73
  • Resistance Level
  • CTNM N/A
  • LFCR $7.48
  • Average True Range (ATR)
  • CTNM 0.00
  • LFCR 0.35
  • MACD
  • CTNM 0.00
  • LFCR 0.06
  • Stochastic Oscillator
  • CTNM 0.00
  • LFCR 67.31

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: